-
Two CEOs met at Seegene headquarters to discuss and agree on Seegene’s vision
-
Seegene’s rapid responses to the COVID-19 pandemic and digital solutions by implementing AI were presented
SEOUL, South Korea, April 8, 2024 /CNW/ — Seegene Inc., a leading South Korean company providing a complete solution for PCR molecular diagnostics, announced today that Prof. Dame Jenny Harrischief executive of the UK Health Safety Agency (UKHSA), visited its headquarters located in Seoul, KoreaOn March 27.
According to the company, Prof. Harris and her delegation engaged in discussions with Dr. Jong-Yun ChunSeegene’s Founder & CEO, and the management team in which she expressed strong agreement in the collective movement to realize Seegene’s vision of “a world free from all diseases”.
Prof. Harris expressed no interest in Seegene’s SG OneSystemTM business, the company’s technology sharing initiative, as well as its advancements in automated artificial intelligence (AI)-driven diagnostic reagent development system and innovative digital solutions that integrate biotechnology (BT) and information technology (IT).
Highlighting Seegene’s rapid response to the Covid-19 pandemic, Prof Harris praised the company’s agility in developing diagnostic reagents within just three weeks and distributing them globally. “We strongly believe that the speed of testing should be faster than the speed of transmission,” explained Dr. Chun, reflecting on the challenges during the pandemic. “We acted quickly, leveraging emergency approvals from governments around the world and leveraging the global distribution network we had in place before the pandemic.”
Seegene has facilitated the rapid and effective isolation of individuals infected with COVID-19 by providing approximately 350 million diagnostic tests in over 100 countries.
“We greatly appreciate the visit of UKHSA, the world’s leading health assurance agency, to Seegene,” said Dr Chun. “We will continue to explore ways to contribute to Korea-UK cooperation, including through our SG OneSystemTM business,” he added.
SG OneSystemTM business, or Seegene’s Technology Sharing Initiative, is a global strategy aimed at eradicating disease. This includes sharing the company’s syndromic quantitative PCR technology and Seegene’s Digitized Development System (SGDDS) with leading companies worldwide. The initiative enables scientists from around the world to contribute directly to the development of locally adapted diagnostic reagents for various diseases affecting humans, animals and plants.
To effectively advance this endeavor, Seegene has built strategic collaborations with industry and academic leaders, including Microsoft and Springer Nature, underscoring its commitment to advancing global health solutions by enhancing technology sharing ininitiative.
About Seegene
Seegene has 23 years of dedicated R&D, manufacturing and business experience around syndromic quantitative PCR technologies, which was highlighted during the COVID-19 pandemic when it provided over 340 million tests for COVID-19 in more than 100 countries worldwide. The key feature of Seegene’s unique syndromic PCR technologies is the ability to simultaneously test 14 pathogens that cause similar symptoms in a single tube and provide quantitative information on the infectivity profile to correlate with disease severity.
See original content for multimedia download: https://www.prnewswire.com/news-releases/seegene-and-uk-health-security-agency-convene-a-summit-to-collectively-realize-a-world- free -from-all-diseases-302110328.html
SOURCE Seegene Inc.
View original media download content: http://www.newswire.ca/en/releases/archive/April2024/08/c8448.html
